CN101563091A - 包含甲壳类动物胃石组分、碳酸钙的组合物及其用途 - Google Patents
包含甲壳类动物胃石组分、碳酸钙的组合物及其用途 Download PDFInfo
- Publication number
- CN101563091A CN101563091A CNA200780045195XA CN200780045195A CN101563091A CN 101563091 A CN101563091 A CN 101563091A CN A200780045195X A CNA200780045195X A CN A200780045195XA CN 200780045195 A CN200780045195 A CN 200780045195A CN 101563091 A CN101563091 A CN 101563091A
- Authority
- CN
- China
- Prior art keywords
- caco
- matter
- chitin
- composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL178495 | 2006-10-05 | ||
| IL178495A IL178495A (en) | 2006-10-05 | 2006-10-05 | Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101563091A true CN101563091A (zh) | 2009-10-21 |
Family
ID=39153987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200780045195XA Pending CN101563091A (zh) | 2006-10-05 | 2007-10-07 | 包含甲壳类动物胃石组分、碳酸钙的组合物及其用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100098774A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2068891B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010505818A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101563091A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007303786B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2665141C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1114930T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2068891T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2439741T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL178495A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2068891T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2068891E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2068891T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008041236A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110121351A (zh) * | 2016-10-25 | 2019-08-13 | 艾玛菲克有限公司 | 用于治疗白血病的无定形碳酸钙 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257750B2 (en) * | 1999-04-30 | 2012-09-04 | Kibow Biotech, Inc. | Calcium carbonate compositions for preventing or treating hyperphosphatemia |
| US8802160B2 (en) | 2007-10-22 | 2014-08-12 | Amorphical Ltd. | Stable amorphous calcium carbonate comprising phosphorylated amino acids |
| JP2015500333A (ja) * | 2011-12-13 | 2015-01-05 | アモーフィカル リミテッド. | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
| EP2882687B1 (en) | 2012-08-07 | 2018-10-10 | Amorphical Ltd. | Method for producing stabilized amorphous calcium carbonate |
| US20150374747A1 (en) * | 2013-02-11 | 2015-12-31 | Amorphical Ltd. | Amorphous calcium carbonate for accelerated bone growth |
| CN103417635B (zh) * | 2013-08-15 | 2015-05-20 | 张荣惠 | 接骨药 |
| CA2956048C (en) | 2014-07-31 | 2023-01-24 | Amorphical Ltd. | Encapsulated amorphous calcium carbonate compositions |
| AU2016273058B2 (en) * | 2015-06-04 | 2021-05-20 | Amorphical Ltd. | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
| US12121538B2 (en) | 2015-06-04 | 2024-10-22 | Amorphical Ltd. | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration |
| CN108471796A (zh) * | 2015-12-14 | 2018-08-31 | 雀巢产品技术援助有限公司 | 用于促进脑的髓鞘形成的营养组合物和婴儿配方食品 |
| EP4233907A3 (en) * | 2015-12-14 | 2024-01-10 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formulas to promote myelination in the brain |
| US11478011B2 (en) | 2015-12-14 | 2022-10-25 | Societe Des Produits Nestle S.A. | Nutritional compositions and infant formula for promoting de novo myealination |
| KR102828392B1 (ko) | 2016-01-18 | 2025-07-02 | 아모피컬 리미티드 | 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘 |
| AU2017210259B2 (en) | 2016-01-18 | 2022-11-03 | Amorphical Ltd. | Stabilized amorphous calcium carbonate as a supplement for cell culture media |
| US12629390B2 (en) | 2016-01-18 | 2026-05-19 | Amorphical Ltd. | Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions |
| MX2022000947A (es) | 2019-07-23 | 2022-04-26 | Amorphical Ltd | Carbonato de calcio amorfo para mejorar el rendimiento deportivo. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237147A (en) | 1974-01-04 | 1980-12-02 | Monsanto Company | Stabilized amorphous calcium carbonate |
| US4199496A (en) * | 1974-09-05 | 1980-04-22 | Johnson Edwin L | Process for the recovery of chemicals from the shells of crustacea |
| US5886012A (en) * | 1989-03-22 | 1999-03-23 | Peter K. T. Pang | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers |
| US20060165784A1 (en) * | 1997-05-06 | 2006-07-27 | Zhao Jin R | Calcium supplement |
| US20030077604A1 (en) * | 2000-10-27 | 2003-04-24 | Yongming Sun | Compositions and methods relating to breast specific genes and proteins |
| JP2002205947A (ja) * | 2000-12-11 | 2002-07-23 | Chafflose Corporation | 水虫治療薬 |
| ES2295391T3 (es) * | 2001-08-16 | 2008-04-16 | Cmp Therapeutics Limited | Microparticulas de quitina y sus usos medicos. |
| JP2004081739A (ja) * | 2002-08-29 | 2004-03-18 | Mitsuru Akashi | ハイドロキシアパタイト−ポリマー複合材料の止血用組成物 |
| AU2003271016A1 (en) * | 2003-09-17 | 2005-04-06 | Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. | Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis |
| ES2447747T3 (es) * | 2004-05-26 | 2014-03-12 | Ben Gurion University Of The Negev Research And Development Authority | Composiciones administrables por vía oral que comprenden carbonato cálcico amorfo estable |
| AU2005296271A1 (en) * | 2004-10-15 | 2006-04-27 | University Of Tennessee Research Foundation | Methods for inducing apoptosis in adipocytes |
-
2006
- 2006-10-05 IL IL178495A patent/IL178495A/en active IP Right Grant
-
2007
- 2007-10-07 WO PCT/IL2007/001211 patent/WO2008041236A2/en not_active Ceased
- 2007-10-07 SI SI200731375T patent/SI2068891T1/sl unknown
- 2007-10-07 CA CA2665141A patent/CA2665141C/en active Active
- 2007-10-07 CN CNA200780045195XA patent/CN101563091A/zh active Pending
- 2007-10-07 PL PL07827185T patent/PL2068891T3/pl unknown
- 2007-10-07 PT PT78271855T patent/PT2068891E/pt unknown
- 2007-10-07 AU AU2007303786A patent/AU2007303786B2/en not_active Ceased
- 2007-10-07 ES ES07827185.5T patent/ES2439741T3/es active Active
- 2007-10-07 EP EP07827185.5A patent/EP2068891B1/en not_active Not-in-force
- 2007-10-07 US US12/443,987 patent/US20100098774A1/en not_active Abandoned
- 2007-10-07 DK DK07827185.5T patent/DK2068891T3/da active
- 2007-10-07 JP JP2009531012A patent/JP2010505818A/ja active Pending
-
2012
- 2012-12-27 US US13/728,508 patent/US8728533B2/en not_active Expired - Fee Related
-
2013
- 2013-12-20 CY CY20131101156T patent/CY1114930T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110121351A (zh) * | 2016-10-25 | 2019-08-13 | 艾玛菲克有限公司 | 用于治疗白血病的无定形碳酸钙 |
Also Published As
| Publication number | Publication date |
|---|---|
| SI2068891T1 (sl) | 2014-02-28 |
| CA2665141A1 (en) | 2008-04-10 |
| PT2068891E (pt) | 2013-12-27 |
| EP2068891A2 (en) | 2009-06-17 |
| DK2068891T3 (da) | 2014-01-13 |
| AU2007303786A1 (en) | 2008-04-10 |
| JP2010505818A (ja) | 2010-02-25 |
| IL178495A (en) | 2014-12-31 |
| ES2439741T3 (es) | 2014-01-24 |
| EP2068891B1 (en) | 2013-09-25 |
| WO2008041236A3 (en) | 2009-05-14 |
| US20130122117A1 (en) | 2013-05-16 |
| IL178495A0 (en) | 2007-02-11 |
| CA2665141C (en) | 2015-03-24 |
| CY1114930T1 (el) | 2016-12-14 |
| WO2008041236A2 (en) | 2008-04-10 |
| US8728533B2 (en) | 2014-05-20 |
| PL2068891T3 (pl) | 2014-03-31 |
| US20100098774A1 (en) | 2010-04-22 |
| AU2007303786B2 (en) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8728533B2 (en) | Composition comprising crustacean gastrolith components and its use | |
| EA012798B1 (ru) | Фармацевтический состав, содержащий карбонат лантана (варианты) | |
| EP0235417A1 (en) | Inorganic mineral composition | |
| CN101352505B (zh) | 一种治疗跌打伤科接骨散 | |
| CN104116022A (zh) | 用于改善妇女更年期综合症的复合保健食品及其制备方法 | |
| CN105770850A (zh) | 一种辅助治疗骨关节疾病的保健品及其制备方法 | |
| WO2019134534A1 (zh) | 一种e-10-羟基-2-癸烯酸在制备防治骨质疏松症的药品或保健品中的应用 | |
| JP2013231073A (ja) | 生物学的平衡化合物の投与による病原体の減衰 | |
| CN106177908A (zh) | 一种具有增加骨密度功能的组合物及其制备方法 | |
| CN103006693A (zh) | 一种二维碳酸钙组合物 | |
| KR102225792B1 (ko) | 에키노크롬 a를 유효성분으로 함유하는 폐경기 증후군의 치료 또는 예방용 약학적 조성물 | |
| JPWO2006043336A1 (ja) | 胃粘膜疾患の治療又は予防のための組成物 | |
| JP2010523563A (ja) | 骨折および骨欠損の処置のためのハーブ製剤 | |
| CN113425846A (zh) | 一种改善骨密度、延缓骨及关节老化的配方 | |
| CN114366764A (zh) | 一种提高人体免疫力,预防和/或治疗骨关节炎的组合物 | |
| CN105560857A (zh) | 一种有改善消化道造影效果的中药制剂 | |
| CN112137087A (zh) | 一种壮骨补钙的组合物、保健品及其制备方法 | |
| RU2076731C1 (ru) | Средство и способ повышения неспецифической резистентности организма при заболеваниях внутренних органов | |
| CN115251339B (zh) | 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法 | |
| CN101831004A (zh) | 透明质酸锶盐系列化合物及其制备方法以及在医药中的应用 | |
| CN110384241A (zh) | 一组有助于骨健康的组合物及其制备方法 | |
| HU200933B (en) | Process for producing pharmaceutical composition for profilacting and treating osteoporosis | |
| CN100479861C (zh) | 硫酸软骨素胶囊剂和片剂的强化性添加剂及其制备方法 | |
| WO2026047691A1 (en) | Synergistic nutraceutical composition to improve calcium absorption | |
| CN106420815A (zh) | 一种药物组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091021 |